• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
By DAVID KATZ Jan 08, 2017 | 02:00 PM EST
Stocks quotes in this article: GILD, JNJ, PFE, MRK, NVS, LLY, BMY, BIIB

This commentary originally appeared on Real Money Pro at 7 a.m. ET Friday, Jan. 6. Click here to learn about this dynamic market information service for active traders.


We expect quite a number of M&A deals in the health-care sector in 2017. In particular, the pharmaceutical and biotechnology space will see heightened levels of activity as major industry players such as Gilead Sciences (GILD) , Johnson & Johnson (JNJ) , Pfizer (PFE) , Merck (MRK) and Novartis (NVS) look to restock their portfolios.

The pathway has likely been further cleared with the recent election of Donald Trump and a Republican Congress, as deals will accelerate after years of regulatory roadblocks under the prior administration.

While we expect much of the activity in the small- and mid-sized names, many of their valuations are pretty rich, and the value lies in betting on their pipelines, which is tougher to handicap.

Our focus today is on some of the larger companies that we also think are vulnerable to takeover activity in the upcoming year.

Three names that we find particularly interesting are Eli Lilly (LLY) , Bristol-Myers Squibb (BMY) and Biogen (BIIB) . These are big companies in their own right. LLY generates $21 billion in revenues and has a market cap of $82 billion. BMY generates $20 billion in revenues and has a market cap of $98 billion. BIIB generates $12 billion in revenues and has a market cap of $64 billion.

Nevertheless, these could be attractive to some of the largest players like Johnson & Johnson, Pfizer, Merck and Novartis, who need bigger acquisition targets to really move the needle.

Investors are bullish on Lilly as several new product launches have recently hit the market, including Trulicity for diabetes, Taltz for psoriasis and new indications for cardiovascular risk in its diabetes drug Jardiance.

Following up these launches is an already strong set of core existing drugs in diabetes, oncology and animal health that are expected to report solid growth in the upcoming years. Lastly, one shouldn't count out Lilly's programs in Alzheimer's, even though they did have a major setback in one of their programs late last year.

The shares aren't cheap at 18.4x earnings. However, Lilly sells at this premium for the high likelihood of a larger company looking to acquire its first-rate cabinet of medicines and for hopes of a big hit in its pipeline.

Bristol-Myers Squibb is also at the top of the takeover heap and selling at an even larger premium at 20x earnings. The big attraction of BMY is its extensive portfolio of immune-oncology (I/O) drugs, led by Opdivo and an Opdivo/Yervoy combination therapy.

Opdivo surprised investors this year by not hitting its lung cancer endpoints. Nevertheless, analysts believe this product will come to market and be a major drug in the space. Furthermore, the Opdivo/Yervoy combination therapy should also be a success. This is in addition to several other key I/O patents, drugs and clinical trials.

To any of the larger players looking to be a key player in the next revolution in oncology via the I/O drugs, Bristol-Meyers Squibb is the most logical acquisition candidate.

Last on the list, Biogen keeps popping up in the rumor mill. The company is the smallest in the group and is best known for its multiple sclerosis drugs, such as Tysabri, Tecfidera and Avonex. The company trades at the lowest valuation of the three discussed at just 14x earnings as key franchises continue to mature and are expected to go generic over the next several years.

Although less dynamic that some of its peers, we think there is real value to their stable product set and emerging pipeline of products in multiple sclerosis and Alzheimer's. The smaller size and attractive valuation level make it a top-of-the-list candidate.

While much is already being priced into potential deals for any of these three potential takeover candidates already occurring, an acquirer will still have to pay a 15% to 20% premium to get a deal done -- so there is still some upside in these names if transactions occur.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, neither Katz nor Matrix clients had any positions in Eli Lilly, Bristol-Myers Squibb or Biogen.

TAGS: Investing | U.S. Equity | Healthcare | Mergers and Acquisitions

More from Healthcare

There Are Market Bright Spots, but I View the July Rally as a Head Fake

Bret Jensen
Aug 3, 2022 10:30 AM EDT

It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.

A Recession Appears Inevitable, but There Are Still Places to Invest

Bret Jensen
Jul 27, 2022 10:30 AM EDT

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.

Change Healthcare Continues to Knock on a Breakout Level

Bruce Kamich
Jul 25, 2022 11:25 AM EDT

The CHNG chart is at an interesting juncture.

The Healing Process Begins for Cano Health

Bruce Kamich
Jul 21, 2022 1:30 PM EDT

Here's how to approach CANO as the shares have made a bottom formation.

With HCA Healthcare, I'm Getting Healthy Indications

Bruce Kamich
Jul 21, 2022 9:20 AM EDT

The healthcare provider is set to report earnings Friday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • 01:44 PM EDT STEPHEN GUILFOYLE

    This Holding Lights Up With Strong Earnings

    Check out the latest from TheStreet's Stocks Under...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login